Investing in Life Sciences
Portfolio Companies
Forward Ventures has built successful, innovative life science companies from start-up through IPO or trade sale.
IPO 2013.
Developed a novel anti-leukemia drug and was acquired by Daiichi-Sankyo in 2014.
Developed a novel anti-staph antibiotic and acquired by DebioPharm in 2014.
IPO 1996.
Developing new drugs for cancer and acquired by Amgen in 2013.
An anti-cancer company that was acquired in 2013 by a private company, TriPhase, supported by Celgene.
A viral vaccine company acquired by Takeda in 2012.
CancerVax (IPO 2003) was an immune-oncology portfolio company that merged with Micromet and was acquired by Amgen in 2012.
Developed a new drug for the treatment of myeloproliferative diseases and was acquired by Sanofi in 2010, later acquired by Impact Biomedicines, a wholly owned subsidiary of Celgene Corporation.
An anti-inflammatory company acquired by Cypres Biosciences in 2008.
IPO 2016. A company developing new immuno-oncology therapeutics for the treatment of cancer.
An active private company founded by Forward Ventures that is developing a novel kappa opioid agonist for the potential treatment of several diseases.
An active private company founded by Forward Ventures developing a novel therapy for EBV-positive malignancies.
Acquirer of Essentialis Therapeutics, a company developing a novel therapy for the orphan disease Prader-Willi syndrome and other dyslipidemias.
Developed monoclonal antibody therapeutics for cancer and acquired by Eisai in 2007.
A cardiovascular focused company and aquired by Merck in 2007.
Developed novel hypnotic drugs and was acquired by Lilly in 2007.
An anticancer company acquired by Pharmion in 2006 and then Celgene in 2007.
Developed a permanent sterilization procedure as an alternative to tubal ligation and was acquired by Hologic in 2007.
An anticancer company acquired by Pharmion in 2006 and then Celgene in 2007.
A company that developed drugs for neurologic diseases and merged with public Epix Pharmaceuticals in 2006.
Developed monoclonal antibodies for cancer and autoimmune disease and was acquired by Medimmune/AstraZeneca in 2005.
IPO 1997. Developed novel anti-cancer and anti-viral drugs and was acquired by GSK in 2005.
IPO 2004. An immunotherapy company for cancer and viral diseases.
IPO 1996. An anti-viral company acquired by Gilead in 2003.
IPO 2000. Developed novel monoclonal antibodies for cancer and acquired by Lilly in 2003.
IPO 1995. A genomics company that is now part of Celera as of 2001.
Developed new drugs using a novel chemistry approach and was acquired by DuPont in 1999.
A gene therapy company acquired by Cell Genesys in 1997 and now part of Biasante as of 2009.
IPO 1994. Developing targeted therapeutics for cancer.
IPO 2006. develops drugs for neurological diseases, including multiple sclerosis.
